Cargando…

Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study

Background: Staphylococcus aureus is a major human pathogen. Panton-Valentine leukocidin (PVL) is a virulence factor produced by some strains that causes leukocyte lysis and tissue necrosis. PVL-associated S. aureus (PVL-SA) predominantly causes skin and soft-tissue infections (SSTIs) but can also c...

Descripción completa

Detalles Bibliográficos
Autores principales: Darboe, Saffiatou, Dobreniecki, Sarah, Jarju, Sheikh, Jallow, Mamadou, Mohammed, Nuredin Ibrahim, Wathuo, Miriam, Ceesay, Buntung, Tweed, Sam, Basu Roy, Robindra, Okomo, Uduak, Kwambana-Adams, Brenda, Antonio, Martin, Bradbury, Richard S., de Silva, Thushan I., Forrest, Karen, Roca, Anna, Lawal, Bolarinde Joseph, Nwakanma, Davis, Secka, Ousman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540874/
https://www.ncbi.nlm.nih.gov/pubmed/31192162
http://dx.doi.org/10.3389/fcimb.2019.00170
_version_ 1783422693148721152
author Darboe, Saffiatou
Dobreniecki, Sarah
Jarju, Sheikh
Jallow, Mamadou
Mohammed, Nuredin Ibrahim
Wathuo, Miriam
Ceesay, Buntung
Tweed, Sam
Basu Roy, Robindra
Okomo, Uduak
Kwambana-Adams, Brenda
Antonio, Martin
Bradbury, Richard S.
de Silva, Thushan I.
Forrest, Karen
Roca, Anna
Lawal, Bolarinde Joseph
Nwakanma, Davis
Secka, Ousman
author_facet Darboe, Saffiatou
Dobreniecki, Sarah
Jarju, Sheikh
Jallow, Mamadou
Mohammed, Nuredin Ibrahim
Wathuo, Miriam
Ceesay, Buntung
Tweed, Sam
Basu Roy, Robindra
Okomo, Uduak
Kwambana-Adams, Brenda
Antonio, Martin
Bradbury, Richard S.
de Silva, Thushan I.
Forrest, Karen
Roca, Anna
Lawal, Bolarinde Joseph
Nwakanma, Davis
Secka, Ousman
author_sort Darboe, Saffiatou
collection PubMed
description Background: Staphylococcus aureus is a major human pathogen. Panton-Valentine leukocidin (PVL) is a virulence factor produced by some strains that causes leukocyte lysis and tissue necrosis. PVL-associated S. aureus (PVL-SA) predominantly causes skin and soft-tissue infections (SSTIs) but can also cause invasive infections such as necrotizing pneumonia. It is carried by both community-associated methicillin susceptible S. aureus (CA-MSSA) and methicillin resistant S. aureus (CA-MRSA). This study aims to determine the prevalence of PVL-SA among patients seen at an urban Gambian hospital and associated antibiotic resistance. Methods: Archived clinical S. aureus (70 invasive bacteraemia and 223 non-invasive SSTIs) from 293 patients were retrieved as well as relevant data from clinical records where available. Antibiotic susceptibility was assessed using disc diffusion according to Clinical Laboratory Standards Institute (CLSI) guidelines. Genomic DNA was extracted and the presence of lukF and lukS PVL genes was detected by conventional gel-based PCR. Result: PVL-SA strains accounted for 61.4% (180/293) of S. aureus isolates. PVL prevalence was high in both Gambian bacteraemia and SSTIs S. aureus strains. Antimicrobial resistance was low and included chloramphenicol (4.8%), cefoxitin (2.4%), ciprofloxacin (3.8%), erythromycin (8.9%), gentamicin (5.5%) penicillin (92.5%), tetracycline (41.0%), and sulfamethoxazole-trimethoprim (24.2%). There was no association of PVL with antimicrobial resistance. Conclusion: PVL expression is high among clinical S. aureus strains among Gambian patients. Reporting of PVL-SA clinical infections is necessary to enable the monitoring of the clinical impact of these strains in the population and guide prevention of the spread of virulent PVL-positive CA-MRSA strains. SUMMARY  Staphylococcus aureus (S. aureus) is a major human pathogen with several virulence factors. We performed a retrospective analysis to investigate the prevalence of one such virulence factor (PVL) amongst clinical S. aureus samples. We found a high prevalence in our setting but antimicrobial resistance including methicillin resistance was low.
format Online
Article
Text
id pubmed-6540874
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65408742019-06-12 Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study Darboe, Saffiatou Dobreniecki, Sarah Jarju, Sheikh Jallow, Mamadou Mohammed, Nuredin Ibrahim Wathuo, Miriam Ceesay, Buntung Tweed, Sam Basu Roy, Robindra Okomo, Uduak Kwambana-Adams, Brenda Antonio, Martin Bradbury, Richard S. de Silva, Thushan I. Forrest, Karen Roca, Anna Lawal, Bolarinde Joseph Nwakanma, Davis Secka, Ousman Front Cell Infect Microbiol Cellular and Infection Microbiology Background: Staphylococcus aureus is a major human pathogen. Panton-Valentine leukocidin (PVL) is a virulence factor produced by some strains that causes leukocyte lysis and tissue necrosis. PVL-associated S. aureus (PVL-SA) predominantly causes skin and soft-tissue infections (SSTIs) but can also cause invasive infections such as necrotizing pneumonia. It is carried by both community-associated methicillin susceptible S. aureus (CA-MSSA) and methicillin resistant S. aureus (CA-MRSA). This study aims to determine the prevalence of PVL-SA among patients seen at an urban Gambian hospital and associated antibiotic resistance. Methods: Archived clinical S. aureus (70 invasive bacteraemia and 223 non-invasive SSTIs) from 293 patients were retrieved as well as relevant data from clinical records where available. Antibiotic susceptibility was assessed using disc diffusion according to Clinical Laboratory Standards Institute (CLSI) guidelines. Genomic DNA was extracted and the presence of lukF and lukS PVL genes was detected by conventional gel-based PCR. Result: PVL-SA strains accounted for 61.4% (180/293) of S. aureus isolates. PVL prevalence was high in both Gambian bacteraemia and SSTIs S. aureus strains. Antimicrobial resistance was low and included chloramphenicol (4.8%), cefoxitin (2.4%), ciprofloxacin (3.8%), erythromycin (8.9%), gentamicin (5.5%) penicillin (92.5%), tetracycline (41.0%), and sulfamethoxazole-trimethoprim (24.2%). There was no association of PVL with antimicrobial resistance. Conclusion: PVL expression is high among clinical S. aureus strains among Gambian patients. Reporting of PVL-SA clinical infections is necessary to enable the monitoring of the clinical impact of these strains in the population and guide prevention of the spread of virulent PVL-positive CA-MRSA strains. SUMMARY  Staphylococcus aureus (S. aureus) is a major human pathogen with several virulence factors. We performed a retrospective analysis to investigate the prevalence of one such virulence factor (PVL) amongst clinical S. aureus samples. We found a high prevalence in our setting but antimicrobial resistance including methicillin resistance was low. Frontiers Media S.A. 2019-05-22 /pmc/articles/PMC6540874/ /pubmed/31192162 http://dx.doi.org/10.3389/fcimb.2019.00170 Text en Copyright © 2019 Darboe, Dobreniecki, Jarju, Jallow, Mohammed, Wathuo, Ceesay, Tweed, Basu Roy, Okomo, Kwambana-Adams, Antonio, Bradbury, de Silva, Forrest, Roca, Lawal, Nwakanma and Secka. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Darboe, Saffiatou
Dobreniecki, Sarah
Jarju, Sheikh
Jallow, Mamadou
Mohammed, Nuredin Ibrahim
Wathuo, Miriam
Ceesay, Buntung
Tweed, Sam
Basu Roy, Robindra
Okomo, Uduak
Kwambana-Adams, Brenda
Antonio, Martin
Bradbury, Richard S.
de Silva, Thushan I.
Forrest, Karen
Roca, Anna
Lawal, Bolarinde Joseph
Nwakanma, Davis
Secka, Ousman
Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study
title Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study
title_full Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study
title_fullStr Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study
title_full_unstemmed Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study
title_short Prevalence of Panton-Valentine Leukocidin (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus aureus in an Urban Gambian Hospital: A 11-Year Period Retrospective Pilot Study
title_sort prevalence of panton-valentine leukocidin (pvl) and antimicrobial resistance in community-acquired clinical staphylococcus aureus in an urban gambian hospital: a 11-year period retrospective pilot study
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540874/
https://www.ncbi.nlm.nih.gov/pubmed/31192162
http://dx.doi.org/10.3389/fcimb.2019.00170
work_keys_str_mv AT darboesaffiatou prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT dobrenieckisarah prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT jarjusheikh prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT jallowmamadou prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT mohammednuredinibrahim prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT wathuomiriam prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT ceesaybuntung prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT tweedsam prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT basuroyrobindra prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT okomouduak prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT kwambanaadamsbrenda prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT antoniomartin prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT bradburyrichards prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT desilvathushani prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT forrestkaren prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT rocaanna prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT lawalbolarindejoseph prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT nwakanmadavis prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy
AT seckaousman prevalenceofpantonvalentineleukocidinpvlandantimicrobialresistanceincommunityacquiredclinicalstaphylococcusaureusinanurbangambianhospitala11yearperiodretrospectivepilotstudy